Table 2c.
Multivariate Cox regression analysis of the risk of biochemical recurrence (BCR) by CAPRA-S variables and STAT5 status in patients with Gleason GG 2 or 3 PC (n = 129)
| Variable | Level | HR | 95% CI | P-Value |
|---|---|---|---|---|
| PSA | 0–6 | Reference | - | - |
| 6.01–10 | 1.461 | (0.41 – 5.24) | 0.560 | |
| 10.01–20 | 2.442 | (0.71 – 8.42) | 0.157 | |
| > 20 | 10.422 | (2.69 – 40.43) | 0.001 | |
| SM | Negative | Reference | - | - |
| Positive | 0.418 | (0.15 – 1.17) | 0.095 | |
| SVI | No | Reference | - | - |
| Yes | 0.800 | (0.27 – 2.41) | 0.692 | |
| EPE | No | Reference | - | - |
| Yes | 2.571 | (0.97 – 6.82) | 0.058 | |
| LNI | No | Reference | - | - |
| Yes | 1.189 | (0.23 – 6.05) | 0.834 | |
| STAT5 | STAT5 FISH−/IHC− | Reference | - | - |
| STAT5 FISH+/IHC− | 2.442 | (0.79 – 7.52) | 0.120 | |
| STAT5 FISH−/IHC+ | 2.543 | (0.91 – 7.07) | 0.074 | |
| STAT5 FISH+/IHC+ | 3.623 | (1.22 – 10.78) | 0.021 |
PSA, prostate specific antigen; SM, surgical margin; SVI, seminal vesicle involvement; EPE, extraprostatic extension; LNI, lymph node involvement.